PKAα/β cat (K17) polyclonal Antibody | BS2648

PKAα/β cat (K17) polyclonal Antibody | BS2648 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB IHC IF

Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200 IF: 1:50~1:200

Background: The second messenger cyclic AMP (cAMP) mediates diverse cellular responses to external signals such as proliferation, ion transport, regulation of metabolism and gene transcription by activation of the cAMP-dependent protein kinase (cAPK or PKA) . Activation of PKA occurs when cAMP binds to the two regulatory subunits of the tetrameric PKA holoenzyme resulting in release of active catalytic subunits. Three catalytic (C) subunits have been identified, designated Cα, Cβ and Cγ, that each represent specific gene products. Cα and Cβ are closely related (93% amino acid sequence similarity), whereas Cγ displays 83% and 79% similarity to Cα and Cβ, respectively. Activation of transcription upon elevation of cAMP levels results from translocation of PKA to the nucleus where it phosphorylates the transcription factor cAMP response element binding protein (CREB) on serine 133 which in turn leads to TFIIB binding to TATA-box-binding protein TBP1, thus linking phospho-CREB to the pol II transcription initiation complex.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: PKAα/β cat (K17) polyclonal Antibody detects endogenous levels of PKAα/β protein.

Molecular Weight: ~ 40, 42 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: cAMP-dependent protein kinase catalytic subunit alpha; PKA C-alpha; PRKACA; PKACA; PKA Ca; cAMP-dependent protein kinase catalytic subunit beta; PKA C-beta; PRKACB; PKACB; PKA Cb;

Immunogen: Synthetic peptide, corresponding to the N-terminus of Human PKAα.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: